{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:42:16Z","timestamp":1792690936541,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40265-019-01143-8","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T11:04:38Z","timestamp":1563188678000},"page":"1263-1276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions"],"prefix":"10.1007","volume":"79","author":[{"given":"Ioannis","family":"Hodges-Mameletzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia A.","family":"Fonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busi","family":"Msimanga-Radebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-8198","authenticated-orcid":false,"given":"Rachel","family":"Baggaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"1143_CR1","unstructured":"UNAIDS. Data 2018 Report, Joint United Nations Programme on HIV\/AIDS (UNAIDS), 2018."},{"key":"1143_CR2","unstructured":"UNAIDS. Miles to go: closing gaps, breaking barriers, righting injustices, UNAIDS, 2018."},{"key":"1143_CR3","unstructured":"World Health Organization. PMTCT strategic vision 2010\u20132015, World Health Organization, 2010."},{"issue":"2 Suppl 1","key":"1143_CR4","doi-asserted-by":"crossref","first-page":"19408","DOI":"10.7448\/IAS.18.2.19408","volume":"18","author":"RC Dellar","year":"2015","unstructured":"Dellar RC, Dlamini S, Karim QA. Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc. 2015;18(2 Suppl 1):19408.","journal-title":"J Int AIDS Soc."},{"issue":"1","key":"1143_CR5","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2352-3018(16)30186-2","volume":"4","author":"T de Oliveira","year":"2017","unstructured":"de Oliveira T, Kharsany AB, Gr\u00e4f T, Cawood C, Khanyile D, Grobler A, Puren A, Madurai S, Baxter C, Karim QA, Karim SS. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. Lancet HIV. 2017;4(1):e41\u201350.","journal-title":"Lancet HIV."},{"key":"1143_CR6","unstructured":"United States Food and Drug Administration, Truvada PrEP indication approval. 2012. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM312290.pdf . Accessed 1 June 2019."},{"key":"1143_CR7","unstructured":"World Health Organization. Guidance on pre-exposure prophylaxis (PrEP) for serodiscordant couples, men, and transgender women who have sex with men at high risk for hiv: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012."},{"key":"1143_CR8","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015."},{"key":"1143_CR9","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2016."},{"issue":"6","key":"1143_CR10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1071\/SH18125","volume":"15","author":"I Hodges-Mameletzis","year":"2018","unstructured":"Hodges-Mameletzis I, Dalal S, Msimanga-Radebe B, Rodolph M, Baggaley R. Going global: the adoption of the World Health Organization'senabling recommendation on oral pre-exposure prophylaxis for HIV. Sex Health. 2018;15(6):489\u2013500.","journal-title":"Sex Health."},{"key":"1143_CR11","volume-title":"WHO handbook for guideline development","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. WHO handbook for guideline development. 2nd ed. Geneva: WHO; 2014.","edition":"2"},{"key":"1143_CR12","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014."},{"key":"1143_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411\u201322.","journal-title":"N Engl J Med"},{"key":"1143_CR14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509\u201318.","journal-title":"N Engl J Med"},{"key":"1143_CR15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O\u2019Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Gran RM. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis. AIDS. 2016;30:1973\u201383.","journal-title":"AIDS"},{"key":"1143_CR16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"1143_CR17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","volume":"14","author":"JM Baeten","year":"2014","unstructured":"Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14:1055\u201364.","journal-title":"Lancet Infect Dis"},{"key":"1143_CR18","unstructured":"Bekker L-G et al. HPTN 067\/ADAPT Cape Town: A comparison of daily and nondaily PrEP dosing in African women. CROI 2015, 23\u201326 February, Seattle. Late breaker poster abstract 978LB."},{"key":"1143_CR19","volume-title":"Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana","author":"F Henderson","year":"2015","unstructured":"Henderson F, Taylor A, Chirwa L, Williams T, Borkowf C, Kasonde M, et al. Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana. Vancouver: IAS; 2015."},{"issue":"2","key":"1143_CR20","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S2352-3018(17)30156-X","volume":"5","author":"LG Bekker","year":"2018","unstructured":"Bekker LG, Roux S, Sebastien E, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067\/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2018;5(2):e68\u201378.","journal-title":"Lancet HIV."},{"issue":"3","key":"1143_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/QAI.0000000000001374","volume":"75","author":"MV Sivay","year":"2017","unstructured":"Sivay MV, Li M, Piwowar-Manning E, et al. Characterization of HIV seroconverters in a TDF\/FTC PrEP study: HPTN 067\/ADAPT. J Acquir Immune Defic Syndr (1999). 2017;75(3):271\u20139.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"8","key":"1143_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002099","volume":"13","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Heffron R, Kidoguchi L, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):1\u201317.","journal-title":"PLoS Med"},{"key":"1143_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.12688\/gatesopenres.12752.1","volume":"1","author":"R Heffron","year":"2017","unstructured":"Heffron R, Ngure K, Odoyo J, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1:3.","journal-title":"Gates Open Res"},{"issue":"1","key":"1143_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/QAI.0000000000001561","volume":"77","author":"M Pyra","year":"2018","unstructured":"Pyra M, Haberer JE, Heffron R, et al. Brief report: PrEP use during periods of HIV risk among east african women in serodiscordant relationships. J Acquir Immune Defic Syndr (1999). 2018;77(1):41\u20135.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"1","key":"1143_CR25","doi-asserted-by":"crossref","first-page":"e01710","DOI":"10.1128\/AAC.01710-17","volume":"62","author":"PL Anderson","year":"2018","unstructured":"Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e01710\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1143_CR26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","volume":"32","author":"CW Hendrix","year":"2016","unstructured":"Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32(1):32\u201343.","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"3","key":"1143_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/QAI.0000000000001093","volume":"73","author":"ST Roberts","year":"2016","unstructured":"Roberts ST, Haberer J, Celum C, et al. Intimate partner violence and adherence to HIV pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: a prospective cohort study. J Acquir Immune Defic Syndr (1999). 2016;73(3):313\u201322.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"10","key":"1143_CR28","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/S2352-3018(17)30110-8","volume":"4","author":"R Heffron","year":"2017","unstructured":"Heffron R, McClelland RS, Balkus JE, et al. Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV. 2017;4(10):e449\u201356.","journal-title":"Lancet HIV."},{"key":"1143_CR29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/ciu355","volume":"59","author":"M Martin","year":"2014","unstructured":"Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Gvetadze RJ, et al. Renal function of participants in the Bangkok tenofovir study\u2014Thailand, 2005\u20132012. Clin Infect Dis. 2014;59:716\u201324.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1143_CR30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/QAI.0000000000001575","volume":"77","author":"KK Mugwanya","year":"2018","unstructured":"Mugwanya KK, Baeten JM, Wyatt C, et al. Brief report: frequency of monitoring kidney function in HIV-uninfected persons using daily oral tenofovir disoproxil fumarate pre-exposure prophylaxis. J Acquir Immune Defic Syndr (1999). 2018;77(2):206\u201311.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"1143_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/QAI.0000000000000858","volume":"71","author":"BG Mirembe","year":"2016","unstructured":"Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, et al. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis. J Acquir Immune Defic Syndr. 2016;71:287\u201394.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1143_CR32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/civ324","volume":"61","author":"K Mulligan","year":"2015","unstructured":"Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, et al. Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:572\u201380.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"1143_CR33","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1086\/375884","volume":"37","author":"MJ Glesby","year":"2003","unstructured":"Glesby MJ. Bone disorders in human immunodeficiency virus infection. Clin Infect Dis. 2003;37(Suppl 2):S91\u20135.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1143_CR34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/INF.0000000000000649","volume":"34","author":"M Della Negra","year":"2015","unstructured":"Della Negra M, De Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MT, Andreatta KN, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321. Pediatr Infect Dis J. 2015;34(4):398\u2013405.","journal-title":"Pediatr Infect Dis J."},{"key":"1143_CR35","unstructured":"World Health Organization. Preventing HIV during pregnancy and breastfeeding in the context of PrEP. Technical Brief. Geneva. World Health Organization; 2017."},{"issue":"2","key":"1143_CR36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAD.0000000000001313","volume":"31","author":"LM Mofenson","year":"2017","unstructured":"Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31(2):213\u201332.","journal-title":"AIDS."},{"key":"1143_CR37","unstructured":"WHO AMS database. http:\/\/www.who.int\/hiv\/amds\/gprm\/en\/ . Accessed 1 June 2019."},{"issue":"2","key":"1143_CR38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/cid\/ciu798","volume":"60","author":"S Ehrhardt","year":"2015","unstructured":"Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015;60(2):275\u20138.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"1143_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001359","volume":"76","author":"JB Nachega","year":"2017","unstructured":"Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, Ford N, Essajee S, Doherty MC, Mills EJ. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;76(1):1\u201312.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"1143_CR40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.2014.8735","volume":"312","author":"NR Mugo","year":"2014","unstructured":"Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Partners PrEP Study Team, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312:362\u201371.","journal-title":"JAMA"},{"key":"1143_CR41","unstructured":"Bunge K, Balkus J, Noguchi L, et al. Pregnancy incidence and outcomes in women receiving tenofovir-based PrEP in the VOICE trial. In: International AIDS conference, July 2015, Vancouver, Canada. Abs. MOPEC480."},{"issue":"9","key":"1143_CR42","doi-asserted-by":"crossref","first-page":"e1002132","DOI":"10.1371\/journal.pmed.1002132","volume":"13","author":"KK Mugwanya","year":"2016","unstructured":"Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med. 2016;13(9):e1002132.","journal-title":"PLoS Med"},{"issue":"3","key":"1143_CR43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/QAI.0000000000000761","volume":"70","author":"AB Kharsany","year":"2015","unstructured":"Kharsany AB, Frohlich JA, Yende-Zuma N, Mahlase G, Samsunder N, Dellar RC, Zuma-Mkhonza M, Abdool Karim SS, Abdool Karim Q. Trends in HIV prevalence in pregnant women in rural South Africa. J Acquir Immune Defic Syndr. 2015;70(3):289\u201395.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"1143_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.2007","author":"SG Hosek","year":"2017","unstructured":"Hosek SG, et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 2017. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.2007 .","journal-title":"JAMA Pediatr"},{"issue":"1","key":"1143_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","volume":"74","author":"SG Hosek","year":"2017","unstructured":"Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer KH, Anderson P, Kiser J, Rooney JF, Wilson CM, Adolescent Trials Network (ATN) for HIVAIDS Interventions. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21\u20139.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"1143_CR46","unstructured":"Gill, K. Pluspills: an open label, safety and feasibility study of oral preexposure prophylaxis (PrEP) in 15-19\u00a0year old adolescents in two sites in South Africa. In: 9th international AIDS Society conference on HIV science, Paris oral abstract session track C: TUAC0207LB, July 2017."},{"key":"1143_CR47","unstructured":"World Health Organization. WHO PrEP implementation module in adolescents and young adults. World Health Organization; 2018. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273172\/WHO-CDS-HIV-18.13-eng.pdf?ua=1 ."},{"key":"1143_CR48","unstructured":"Unitaid website. https:\/\/unitaid.org\/investment-area\/hiv-prevention\/ . Accessed 1 June 2019."},{"key":"1143_CR49","unstructured":"European Medicines Agency, summary of opinion on Truvada. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000594\/WC500240366.pdf . Accessed 1 June 2019."},{"key":"1143_CR50","unstructured":"United States Food and Drug Administration, approval letter for adolescent indication. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/021752Orig1s055ltr.pdf . Accessed 1 June 2019."},{"key":"1143_CR51","unstructured":"World Health Organization. Technical update on appropriate medicines options for pre-exposure prophylaxis (PrEP). A review of the evidence from animal studies, human pharmacology, and human clinical trials. World Health Organization, 2018."},{"issue":"9883","key":"1143_CR52","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390.","journal-title":"Lancet."},{"issue":"1","key":"1143_CR53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAI.0b013e31828ece33","volume":"64","author":"LA Grohskopf","year":"2013","unstructured":"Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O\u02bchara B, Ackers ML, Rose CE, Grant RM, Paxton LA, Buchbinder SP. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79\u201386.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"1143_CR54","unstructured":"Ensaio cl\u00ednico de fase II comparando a utiliza\u00e7\u00e3o de Lamivudina\/Tenofovir (3TC\/TDF) Emtricitabina\/Tenofovir (FTC\/TDF)\u00bf como estrat\u00e9gias de Profilaxia Pr\u00e9 Exposi\u00e7\u00e3o (PrEP) ao HIV entre gays, outros homens que fazem sexo com homens e pessoas trans. Faculdade de Medicina da Universidade Federal de Minas Gerais."},{"issue":"5996","key":"1143_CR55","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168\u201374.","journal-title":"Science."},{"issue":"6341","key":"1143_CR56","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.aai9383","volume":"356","author":"NR Klatt","year":"2017","unstructured":"Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, No\u00ebl-Romas L, Grobler A, Westmacott G, Xie IY, Butler J, Mansoor L, McKinnon LR, Passmore JS, Abdool Karim Q, Abdool Karim SS, Burgener AD. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science. 2017;356(6341):938\u201345.","journal-title":"Science."},{"issue":"22","key":"1143_CR57","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med."},{"issue":"22","key":"1143_CR58","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133\u201343.","journal-title":"N Engl J Med."},{"key":"1143_CR59","unstructured":"Brown E, Palanee-Philips T, Marzinke M, Hendrix C, Dezutti C, Soto-Torre L, Baeten J. Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection. In: Abstract TUAC0105LB. 21st international AIDS conference (AIDS 2016). Durban, South Africa, July 18\u201322, 2016."},{"key":"1143_CR60","unstructured":"Baeten J et al. High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring. In: 25th conference on retroviruses and opportunistic infections (CROI 2018), Boston, abstract 143LB, 2018."},{"key":"1143_CR61","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02858037, Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02858037 ."},{"key":"1143_CR62","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02862171, To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02862171 ."},{"key":"1143_CR63","unstructured":"Multi-purpose technologies information, World Health Organization; 2018. http:\/\/www.who.int\/reproductivehealth\/topics\/linkages\/mpts\/en\/ ."},{"issue":"2","key":"1143_CR64","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1113\/JP271694","volume":"595","author":"SB Smith","year":"2017","unstructured":"Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017;595(2):451\u201363.","journal-title":"J Physiol."},{"issue":"4","key":"1143_CR65","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17425247.2017.1270938","volume":"14","author":"J das Neves","year":"2017","unstructured":"das Neves J, Sarmento B. Antiretroviral drug-loaded nanoparticles-in-films: a new option for developing vaginal microbicides? Expert Opin Drug Deliv. 2017;14(4):449\u201352.","journal-title":"Expert Opin Drug Deliv"},{"key":"1143_CR66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jconrel.2015.08.042","volume":"219","author":"A Nelson","year":"2015","unstructured":"Nelson A, Zhang X, Ganapathi U, Szekely Z, Flexner CW, Owen A, Sinko PJ. Drug delivery strategies and systems for HIV\/AIDS pre-exposure prophylaxis (PrEP) and treatment. J Control Release. 2015;219:669\u201380.","journal-title":"J Control Release."},{"key":"1143_CR67","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02720094, Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate\/Emtricitabine (TDF\/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720094 ."},{"key":"1143_CR68","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03164564, Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF\/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03164564 ."},{"key":"1143_CR69","unstructured":"World Health Organization. Global health sector strategy on sexually transmitted infections, 2016\u20132021. Geneva: World Health Organization; 2016."},{"key":"1143_CR70","unstructured":"World Health Organization. cervical cancer control: a guide to essential practice, 2nd edn. World Health Organization; 2014. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/144785\/9789241548953_eng.pdf;jsessionid=50992AF8EFBA400059A5C619FF0D2F97?sequence=1 ."},{"issue":"9069","key":"1143_CR71","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(97)02190-9","volume":"349","author":"MS Cohen","year":"1997","unstructured":"Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, AIDSCAP Malawi Research Group, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet. 1997;349(9069):1868\u201373.","journal-title":"Lancet."},{"issue":"7","key":"1143_CR72","doi-asserted-by":"crossref","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344.","journal-title":"PLoS Med."},{"issue":"2","key":"1143_CR73","doi-asserted-by":"crossref","first-page":"e1002511","DOI":"10.1371\/journal.pmed.1002511","volume":"15","author":"EA Torrone","year":"2018","unstructured":"Torrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, Looker KJ, McCormack S, McGrath N, van de Wijgert JHHM, Watson-Jones D, Low N, Gottlieb SL, STIMA Working Group. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018;15(2):e1002511.","journal-title":"PLoS Med."},{"issue":"4","key":"1143_CR74","doi-asserted-by":"crossref","first-page":"e0196209","DOI":"10.1371\/journal.pone.0196209","volume":"13","author":"NJ Garrett","year":"2018","unstructured":"Garrett NJ, Osman F, Maharaj B, Naicker N, Gibbs A, Norman E, et al. Beyond syndromic management: opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. PLoS One. 2018;13(4):e0196209.","journal-title":"PLoS One."},{"issue":"3","key":"1143_CR75","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/OLQ.0000000000000931","volume":"46","author":"CM Hoffman","year":"2019","unstructured":"Hoffman CM, Mbambazela N, Sithole P, Morr\u00e9 SA, Dubbink JH, Railton J, McIntyre JA, Kock MM, Peters RPH. Provision\u00a0of\u00a0sexually\u00a0transmitted\u00a0infection\u00a0services\u00a0in a mobile clinic reveals high unmet need in remote areas of South Africa: a cross-sectional study. Sex Transm Dis. 2019;46(3):206\u201312.","journal-title":"Sex Transm Dis."},{"key":"1143_CR76","unstructured":"Celum C. Oral pre-exposure prophylaxis for prevention, MOSA3401. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"issue":"1","key":"1143_CR77","doi-asserted-by":"crossref","first-page":"e0170773","DOI":"10.1371\/journal.pone.0170773","volume":"12","author":"E Korenromp","year":"2017","unstructured":"Korenromp E, Wi T, Resch S, Stover J, Broutet N. Costing of national STI program implementation for the global STI control strategy for the health sector, 2016\u20132021. PLoS One. 2017;12(1):e0170773.","journal-title":"PLoS One."},{"key":"1143_CR78","unstructured":"World Health Organization. WHO unmet need for family planning, WHO website. http:\/\/www.who.int\/reproductivehealth\/topics\/family_planning\/unmet_need_fp\/en\/ ."},{"key":"1143_CR79","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division (2017). World Family Planning 2017\u2014Highlights (ST\/ESA\/SER.A\/414)."},{"issue":"5","key":"1143_CR80","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/COH.0b013e3283632bd7","volume":"8","author":"R Wilcher","year":"2013","unstructured":"Wilcher R, Petruney T, Cates W. The role of family planning in elimination of new pediatric HIV infection. Curr Opin HIV AIDS. 2013;8(5):490\u20137.","journal-title":"Curr Opin HIV AIDS."},{"issue":"6","key":"1143_CR81","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.contraception.2018.01.007","volume":"97","author":"D Seidman","year":"2018","unstructured":"Seidman D, Weber S, Carlson K, Witt J. Family planning providers\u2019 role in offering PrEP to women. Contraception. 2018;97(6):467\u201370.","journal-title":"Contraception."},{"issue":"5","key":"1143_CR82","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s10461-016-1663-8","volume":"21","author":"CH Bien","year":"2017","unstructured":"Bien CH, Patel VV, Blackstock OJ, Felsen UR. Reaching key populations: PrEP uptake in an urban health care system in the Bronx, New York. AIDS Behav. 2017;21(5):1309\u201314.","journal-title":"AIDS Behav"},{"issue":"7","key":"1143_CR83","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/09540121.2017.1286287","volume":"29","author":"OJ Blackstock","year":"2017","unstructured":"Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866\u20139.","journal-title":"AIDS Care."},{"issue":"4","key":"1143_CR84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAI.0000000000001605","volume":"77","author":"CA Flash","year":"2018","unstructured":"Flash CA, Adegboyega OO, Yu X, et al. Correlates of linkage to HIV preexposure prophylaxis among HIV-testing clients. J Acquir Immune Defic Syndr (1999). 2018;77(4):365\u201372.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"1143_CR85","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jnma.2017.12.006","volume":"110","author":"HA Kwakwa","year":"2018","unstructured":"Kwakwa HA, Bessias S, Sturgis D, et al. Engaging United States black communities in HIV pre-exposure prophylaxis: analysis of a PrEP engagement cascade. J Natl Med Assoc. 2018;110:480\u20135.","journal-title":"J Natl Med Assoc."},{"issue":"5","key":"1143_CR86","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Hurley LB, Hare CB, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr (1999). 2016;73(5):540\u20136.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"3","key":"1143_CR87","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/QAI.0000000000001004","volume":"72","author":"J Rajchgot","year":"2016","unstructured":"Rajchgot J, Siemieniuk RA, Sivachandran N, et al. Feasibility of HIV pre-exposure prophylaxis as part of routine care in Toronto. Canada. J Acquir Immune Defic Syndr (1999). 2016;72(3):e80\u20131.","journal-title":"Canada. J Acquir Immune Defic Syndr (1999)"},{"key":"1143_CR88","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/cid\/ciy160","volume":"67","author":"LK Rusie","year":"2018","unstructured":"Rusie LK, Orengo C, Burrell D, et al. PrEP Initiation and retention in care over five years, 2012\u20132017: are quarterly visits too much? Clin Infect Dis. 2018;67:283\u20137.","journal-title":"Clin Infect Dis."},{"issue":"5","key":"1143_CR89","doi-asserted-by":"crossref","first-page":"632.e631","DOI":"10.1016\/j.ajog.2016.06.020","volume":"215","author":"DL Seidman","year":"2016","unstructured":"Seidman DL, Weber S, Timoney MT, et al. Use of HIV pre-exposure prophylaxis during the preconception, antepartum and postpartum periods at two United States medical centers. Am J Obstet Gynecol. 2016;215(5):632.e631\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1143_CR90","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0000000000001598","volume":"77","author":"P van Epps","year":"2018","unstructured":"van Epps P, Maier M, Lund B, et al. Medication adherence in a nationwide cohort of veterans initiating pre-exposure prophylaxis (PrEP) to prevent HIV infection. J Acquir Immune Defic Syndr (1999). 2018;77(3):272\u20138.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"1143_CR91","unstructured":"Mera Giler, Magnuson RD, Trevor H, Bush S, Rawlings R, McCallister S. Changes in Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2012\u20132016). In: 9th international AIDS Society conference on HIV Science, Paris, abstract 1614, July 2017."},{"key":"1143_CR92","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","volume":"28","author":"AJ Siegler","year":"2018","unstructured":"Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, Jones PhDJ, Castel A, Yeung H, Kramer M, McCallister S, Sullivan PS. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28:841\u20139.","journal-title":"Ann Epidemiol."},{"issue":"3","key":"1143_CR93","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40121-017-0159-9","volume":"6","author":"JL Bailey","year":"2017","unstructured":"Bailey JL, Molino ST, Vega AD, Badowski M. A review of HIV pre-exposure prophylaxis: the female perspective. Infect Dis Ther. 2017;6(3):363\u201382.","journal-title":"Infect Dis Ther."},{"key":"1143_CR94","unstructured":"National Department of Health, Republic of South Africa. National policy on HIV pre-exposure prophylaxis (PrEP) and test and treat (T&T) (2016)."},{"key":"1143_CR95","unstructured":"Pillay D. Factors influencing initiation, continuation and discontinuation of oral PrEP at selected facilities in South Africa. In: Oral abstract presentation WEAE0401. 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR96","unstructured":"DREAMS Partnership. 2019. [Internet] Available at: https:\/\/www.pepfar.gov\/partnerships\/ppp\/dreams . Accessed 1 June 2019."},{"key":"1143_CR97","unstructured":"World Health Organization. Models of implementation of PrEP: lessons learnt from Kenya. \u201cFrom demonstration to national adoption\u201d. Non-commercial satellite. FRSA05. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR98","unstructured":"Erungu EM, Mugwanya KM, Bukusi EA, Mugo NR, Odoyo J, Wamoni E, Ngure K, Morton J, O\u2019Malley G, Masyuko S, Mukui I, Haberer JE, Anderson PL, Baeten J. High PrEP use in African men and women continuing PrEP in public-health HIV clinics. In: CROI, March 4\u20137, 2019. Seattle, Washington. Abstract number 992."},{"key":"1143_CR99","unstructured":"Pillay Y. Challenges of South Africa\u2019s sex worker PrEP programme: lessons learned, moving towards to other key populations. Satellite presentation TUSA1703. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR100","unstructured":"Cowan F. PrEP in populations at high risk: prioritizing populations and positioning PrEP. WESA1303. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR101","unstructured":"Matse S. Reaching those most at-risk through a general population approach: PrEP in the context of a generalized HIV epidemic. WESA1304. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR102","unstructured":"PrEP Watch. 2019. [Internet] Available at: https:\/\/www.prepwatch.org\/ . Accessed 1 June 2019."},{"key":"1143_CR103","unstructured":"PrEP Watch, Nigeria Demonstration Project. 2019. [Internet] Available at: https:\/\/www.prepwatch.org\/nigeria\/ . Accessed 1 June 2019."},{"key":"1143_CR104","unstructured":"WHO country profile, India. 2019 [Internet] Available at: http:\/\/www.who.int\/gho\/countries\/ind\/country_profiles\/en\/ . Accessed 1 June 2019."},{"key":"1143_CR105","unstructured":"Reza-Paul S. Community-led PrEP delivery: getting it right, WESA1305. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"issue":"5","key":"1143_CR106","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","volume":"21","author":"K Koechlin","year":"2017","unstructured":"Koechlin K, Fonner V, Dalglish S, O\u2019Reilly K, Baggaley R, Grant R, Rodolph M, Hodges-Mameletzis I, Kennedy C. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21(5):1325\u201335.","journal-title":"AIDS Behav."},{"key":"1143_CR107","unstructured":"Hirschhorn L, Brown Rayna, Friedman EE, Christeller C, Greene G, Bender A, Bouris A, Modali L, Johnson AK, Pickett J, Ridgway J. Women\u2019s PrEP knowledge, attitudes, preferences, and experience in Chicago. In: March 4\u20137, 2019, Seattle, Washington. Abstract Number:\u00a0978."},{"key":"1143_CR108","unstructured":"COMPASS initiative. 2019. [Internet] Available at: https:\/\/www.gilead.com\/purpose\/partnerships-and-community\/compass . Accessed 1 June 2019."},{"key":"1143_CR109","unstructured":"Sophia Forum. 2019. [Internet] Available at: http:\/\/womenandprep.org.uk . Accessed 1 June 2019."},{"key":"1143_CR110","unstructured":"OPTIONS Consortium. 2019. [Internet] Available at: https:\/\/www.fhi360.org\/projects\/optimizing-prevention-technology-introduction-schedule-options-consortium . Accessed 1 June 2019."},{"issue":"12","key":"1143_CR111","doi-asserted-by":"crossref","first-page":"e0208167","DOI":"10.1371\/journal.pone.0208167","volume":"13","author":"J Saul","year":"2018","unstructured":"Saul J, Bachman G, Allen S, Toiv NF, Cooney C, Beamon T. The DREAMS core package of interventions: a comprehensive approach to preventing HIV among adolescent girls and young women. PLoS One. 2018;13(12):e0208167.","journal-title":"PLoS One."},{"key":"1143_CR112","unstructured":"She Conquers. 2019 [Internet] Available at: http:\/\/sheconquerssa.co.za . Accessed 1 June 2019."},{"key":"1143_CR113","unstructured":"UNAIDS 90-90-90 strategy. [Internet] Available at: http:\/\/www.unaids.org\/en\/90-90-90 . Accessed 1 June 2019."},{"key":"1143_CR114","unstructured":"World Health Organization. Global health sector strategy on HIV 2016\u20132021. Geneva: World Health Organization; 2016."},{"key":"1143_CR115","unstructured":"FP 2020 website. [Internet] Available at: http:\/\/www.familyplanning2020.org\/ . Accessed 1 June 2019."},{"key":"1143_CR116","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(14)61830-4","volume":"385","author":"C Garc\u00eda-Moreno","year":"2015","unstructured":"Garc\u00eda-Moreno C, Zimmerman C, Morris-Gehring A, et al. Addressing violence against women: a call to action. Lancet. 2015;385:1685\u201395.","journal-title":"Lancet"},{"issue":"8","key":"1143_CR117","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/aid.2018.0031","volume":"34","author":"H Janes","year":"2018","unstructured":"Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, Gilbert PB, Gray GE. Weighing the evidence of efficacy of oral PrEP for HIV prevention in women in Southern Africa. AIDS Res Hum Retroviruses. 2018;34(8):645\u201356.","journal-title":"AIDS Res Hum Retroviruses."},{"key":"1143_CR118","unstructured":"World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/324797\/WHO-CDS-HIV-19.7-eng.pdf?ua=1 . Accessed 1 June 2019."},{"issue":"1","key":"1143_CR119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3122\/jabfm.2016.01.150223","volume":"29","author":"J Conniff","year":"2016","unstructured":"Conniff J, Evensen AJ. Preexposure prophylaxis (PrEP) for HIV prevention: the primary care perspective. Am Board Fam Med. 2016;29(1):143\u201351.","journal-title":"Am Board Fam Med."},{"issue":"14","key":"1143_CR120","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jama.2019.2945","volume":"321","author":"M Gandhi","year":"2019","unstructured":"Gandhi M, Spinelli MA, Mayer KH. Addressing the sexually transmitted infection and HIV syndemic. JAMA. 2019;321(14):1356\u20138.","journal-title":"JAMA."},{"key":"1143_CR121","volume-title":"Framework for the implementation of pre-exposure prophylaxis of HIV in Kenya","author":"National AIDS and STI Control Programme (NASCOP), Ministry of Health","year":"2017","unstructured":"National AIDS and STI Control Programme (NASCOP), Ministry of Health. Framework for the implementation of pre-exposure prophylaxis of HIV in Kenya. Nairobi: NASCOP; 2017."},{"issue":"4","key":"1143_CR122","doi-asserted-by":"crossref","first-page":"e0125458","DOI":"10.1371\/journal.pone.0125458","volume":"10","author":"A Corneli","year":"2015","unstructured":"Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS One. 2015;10(4):e0125458.","journal-title":"PLoS One."},{"issue":"16","key":"1143_CR123","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/QAD.0000000000000801","volume":"29","author":"A van der Straten","year":"2015","unstructured":"van der Straten A, Montgomery ET, Musara P, Etima J, Naidoo S, Laborde N, Hartmann M, Levy L, Bennie T, Cheng H, Piper J, Grossman CI, Marrazzo J, Mensch B, Microbicide Trials Network-003D Study Team. Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015;29(16):2161\u201371.","journal-title":"AIDS."},{"issue":"2","key":"1143_CR124","doi-asserted-by":"crossref","first-page":"e25081","DOI":"10.1002\/jia2.25081","volume":"21","author":"R Eakle","year":"2018","unstructured":"Eakle R, Bourne A, Mbogua J, Mutanha N, Rees H. Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. J Int AIDS Soc. 2018;21(2):e25081.","journal-title":"J Int AIDS Soc."},{"issue":"5","key":"1143_CR125","doi-asserted-by":"crossref","first-page":"e0197143","DOI":"10.1371\/journal.pone.0197143","volume":"13","author":"J Davey","year":"2018","unstructured":"Davey J, Farley E, Towriss C, Gomba Y, Bekker LG, Gorbach P, Shoptaw S, Coates T, Myer L. Risk perception and sex behaviour in pregnancy and breastfeeding in high HIV prevalence settings: programmatic implications for PrEP delivery. PLoS One. 2018;13(5):e0197143.","journal-title":"PLoS One."},{"key":"1143_CR126","unstructured":"Mera R et al. Changes in Truvada for HIV pre-exposure prophylaxis utilization in the USA: 2012\u20132016. In: 9th international AIDS Society conference on HIV science, Paris, abstract WEPEC0919, July 2017."},{"key":"1143_CR127","unstructured":"Annual HIV epidemiological report. San Francisco City Health Department. 2017. Available at: https:\/\/www.sfdph.org\/dph\/files\/reports\/RptsHIVAIDS\/AnnualReport2017-Green-20180904-Web.pdf . Accessed 1 June 2019."},{"key":"1143_CR128","unstructured":"Grulich A, Guy RJ, Amin J, et al. Rapid reduction in HIV diagnoses after targeted PrEP implementation in NSW, Australia. In: 25th conference on retroviruses and opportunistic infections 2018, abstract 88."},{"issue":"11","key":"1143_CR129","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/S2352-3018(17)30181-9","volume":"4","author":"N Nwokolo","year":"2017","unstructured":"Nwokolo N, Hill A, McOwan A, Pozniak A. Rapidly declining HIV infection in MSM in central London. Lancet HIV. 2017;4(11):e482\u20133.","journal-title":"Lancet HIV."},{"key":"1143_CR130","unstructured":"Sullivan P et al. The impact of pre-exposure prophylaxis with TDF\/FTC on HIV diagnoses, 2012\u20132016, United States. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, abstract LBPEC036, 2018."},{"key":"1143_CR131","unstructured":"Ogaz D, Miltz A, Desai S, Saunders J, Charlett A, Gill N, Mohammed H. Preparing for PrEP in England: prevalence and incidence of HIV and bacterial STIs. March 4\u20137, 2019; Seattle, Washington. Abstract Number 48."},{"issue":"8","key":"1143_CR132","doi-asserted-by":"crossref","first-page":"e0202830","DOI":"10.1371\/journal.pone.0202830","volume":"13","author":"S Paparini","year":"2018","unstructured":"Paparini S, Nutland W, Rhodes T, Nguyen VK, Anderson J. DIY HIV prevention: formative qualitative research with men who have sex with men who source PrEP outside of clinical trials. PLoS One. 2018;13(8):e0202830.","journal-title":"PLoS One."},{"key":"1143_CR133","unstructured":"Digolo L. Reaching adolescents and young persons with PrEP. In: FRSA0503, 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR134","unstructured":"Reza-Paul S. Community led PrEP delivery: getting it right. Satellite presentation WESA1305. In: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR135","unstructured":"Mugwanya K et al. Uptake of PrEP within clinics providing integrated family planning and PrEP services: results from a large implementation program in Kenya. In: Oral abstract presentation TUAC0304. 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR136","unstructured":"Sarr M. Retention in care for HIV pre-exposure prophylaxis (PrEP) among sex workers of four public health centers in Senegal. In: Oral abstract TUAC0301. 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR137","unstructured":"Gombe M et al. Integrating oral HIV pre-exposure prophylaxis (PrEP) in a public family planning facility and youth center to inform national roll out in Zimbabwe. In: Oral abstract presentation TUAC0307LB. 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR138","unstructured":"Cowan F. PrEP in populations at high risk: prioritizing populations and positioning PrEP, WESA1303. In\u00a0: 22nd international AIDS conference (AIDS 2018), Amsterdam, July 2018."},{"key":"1143_CR139","unstructured":"World Health Organization. WHO PrEP implementation tool, module for monitoring and evaluation, World Health Organization, 2018. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273172\/WHO-CDS-HIV-18.13-eng.pdf?ua=1 ."},{"key":"1143_CR140","unstructured":"Davey DJ, Bekker LG, Gomba Y, Myer L, Coates TJ, Johnson LF. Modeling the impact of PrEP for pregnant and breastfeeding women in South Africa. In: Conference dates and location: March 4\u20137, 2019, Seattle, Washington. Abstract number 776."},{"key":"1143_CR141","unstructured":"Global PrEP coalition, World Health Organization, 2019. [Internet] Available at: http:\/\/www.who.int\/hiv\/prep\/global-prep-coalition\/en . Accessed 1 June 2019."},{"key":"1143_CR142","unstructured":"World Health Organization. 20th Essential Medicines List. (2017). https:\/\/www.who.int\/medicines\/news\/2017\/20th_essential_med-list\/en\/ . Accessed 1 June 2019."},{"issue":"2","key":"1143_CR143","first-page":"238","volume":"215","author":"RM Gulick","year":"2017","unstructured":"Gulick RM, Wilkin TJ, Chen YQ, et al. Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069\/ACTG A5305). J Infect Dis. 2017;215(2):238\u201346.","journal-title":"J Infect Dis."},{"key":"1143_CR144","unstructured":"Bunge KE et al. Phase I trial to assess safety, PK, and PD of film and gel formulations of tenofovir. In: CROI 2016, Boston. Poster abstract 871."},{"issue":"2","key":"1143_CR145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4155\/tde.14.110","volume":"6","author":"AS Ham","year":"2015","unstructured":"Ham AS, Buckheit RW. Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors. Ther Deliv. 2015;6(2):217\u201329.","journal-title":"Ther Deliv."},{"key":"1143_CR146","unstructured":"Aidsmap. 2019. [Internet]. http:\/\/www.aidsmap.com\/Implants-and-injectables-PrEP-in-the-future\/page\/3110737 . Accessed 1 June 2019."},{"key":"1143_CR147","doi-asserted-by":"crossref","unstructured":"Derby N et al. Griffithsin\/carrageenan inserts prevent SHIV, HSV-2, and HPV infections in vivo. In: CROI 2018, Boston. Oral abstract 84.","DOI":"10.1038\/s41467-018-06349-0"},{"key":"1143_CR148","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03467347, PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT034673412047 ."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01143-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T22:33:42Z","timestamp":1663972422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01143-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":148,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01143-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"15 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ioannis Hodges-Mameletzis, Virginia Fonner, Shona Dalal, Nelly Mugo, Busi Msimnga-Radebe, and Rachel Baggaley declare that they have no conflicts of interest relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}